BENITIONSClinical Trial Intelligence

A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus

1期 已完成 NCT05086445

适应症Diabetes Mellitus, Type 2
分期1期
申办方Eli Lilly and Company
状态已完成
受试者人数62 人
干预(药物)LY3502970
开始日期2021年11月12日
完成日期2022年9月5日
结果公布日2026年7月16日

摘要

The main purpose of this study is to learn about the side effects of LY3502970 when given to Japanese participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last up to 24 weeks, inclusive of screening and will include 10 visits to the study center.

Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Baseline Through Follow-Up (Up To Week 15) · Participants

Placebo - Part A2 Participants
2 mg LY3502970 - Part A5 Participants
3 mg LY3502970 - Part A5 Participants
Placebo QD - Part B4 Participants
2(or 3)/3/6/12 mg LY3502970 QD - Part B11 Participants
2/3/6/8/12/24 mg LY3502970 QD - Part B12 Participants

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

全部试验

本页整理自 ClinicalTrials.gov 的公开数据,不构成医疗建议,也不构成投资建议。请务必咨询专业医师。